Related references
Note: Only part of the references are listed.Volumetric segmentation of glioblastoma progression compared to bidimensional products and clinical radiological reports
Erik Magnus Berntsen et al.
ACTA NEUROCHIRURGICA (2020)
Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study
Philipp Kickingereder et al.
LANCET ONCOLOGY (2019)
Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement
Ken Chang et al.
NEURO-ONCOLOGY (2019)
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial
Renske Gahrmann et al.
NEURO-ONCOLOGY (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma
Cecelia Elizabeth Gzell et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study
Jerrold L. Boxerman et al.
NEURO-ONCOLOGY (2013)
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
Thierry Gorlia et al.
EUROPEAN JOURNAL OF CANCER (2012)
Measurement of tumor size in adult glioblastoma: Classical cross-sectional criteria on 2D MRI or volumetric criteria on high resolution 3D MRI?
Mei-Yun Wang et al.
EUROPEAN JOURNAL OF RADIOLOGY (2012)
Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria
Alexander Radbruch et al.
NEURO-ONCOLOGY (2012)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
Teri N. Kreisl et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
F. M. Iwamoto et al.
NEUROLOGY (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Time course of imaging changes of GBM during extended bevacizumab treatment
Suchitra Ananthnarayan et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability
Paul A. Yushkevich et al.
NEUROIMAGE (2006)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors
KE Warren et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
